Respiratory

Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.

The drug had previously been granted a breakthrough therapy designation by the FDA.

The average US household spent $645 on OTC products in 2022.

According to posters presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, pharmacists wish to play a bigger role in educating young people about the risks of vaping.

Moderna, Merck, and Pfizer-BioNTech are leading the charge with new vaccines for respiratory viruses in development.

AstraZeneca is the second pharmaceutical company to cap out-of-pocket costs for eligible patients.

See what's trending in pharmacy with a preview the Drug Topics March issue.

Researchers assessed the benefits of electronic cigarettes for tobacco cessation compared with varenicline and nicotine chewing gum.

Test your pharmacy news knowledge with our weekly quiz.

The out-of-pocket price cap applies to all inhalers in the company’s portfolio and will launch on June 1, 2024.

Pfizer's RSV vaccine received FDA approval on May 31, 2023.

Improvement across all asthma control parameters was achieved after 12 months of biologic treatment with mepolizumab, benralizumab, and omalizumab.

In order to provide the best care, it’s crucial that pharmacists stay up-to-date on the latest guidance and data for flu, COVID-19, and RSV—even when that information is constantly changing.

These OTC products are recommended to address a variety of symptoms that occur during cold and flu seasons.

Patients with COPD are typically characterized by lower physical activity (PA); lower PA levels are associated with both decreased lung function and accelerated deterioration of lung function.

June 7, 2024 is the target PDUFA date for the additional indication of GSK's respiratory syncytial virus vaccine Arexvy.

In response to a surge in cases of COVID-19, flu, and RSV, hospitals are reinstating mask guidelines to avoid adverse capacity outcomes and staffing shortages seen in prior years.

The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.

Higher concentrations of omega-3 fatty acids were associated with the ability to exchange carbon dioxide more efficiently and longer transplant-free survival.

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

A new report from the CDC demonstrated a decrease in cigarette smoking across all race and ethnic groups from 2016 to 2022, illustrating a promising trend with potential public health benefits.

In January 2024, Sanofi and AstraZenenca will release 230,000 additional doses of nirsevimab-alip, heeding guidance from the CDC to leverage all tools to increase immunizations against RSV.

Lupin gained FDA approval for varenicline tablets (0.5 mg and 1 mg) and launched its already-approved Turqoz (norgestrel and ethinyl estradiol) tablets USP, 0.3 mg/0.03 mg earlier this month.

Immunizations against influenza, COVID-19, and RSV are lower than they were this time last year, and hospitalizations have increased across all age groups.

A phase 4 study demonstrated that biologic therapies can control severe asthma while simultaneously helping patients minimize or eliminate harms associated with inhaled corticosteroids.

The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.

The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.

Maintaining a healthy diet before pregnancy was associated with a 10% reduced risk of children developing 'transient early' and 'persistent' wheeze patterns.

The capsule was developed by the pharmaceutical company Lupin and is a generic equivalent to Boehringer Ingelheim’s Spiriva HandiHaler.